Hepatocellular CarcinomaPhase 3ARTEMIDE-HCC01NCT06921785

Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular Carcinoma

A Phase 3 study testing Tremelimumab, Rilvegostomig and Bevacizumab in people with Hepatocellular Carcinoma, run by AstraZeneca at 226 sites in 20 countries.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts

Official record

Search all trials

Trial summary

This is a Phase III, randomised, open-label, sponsor-blinded, 3-arm, multicentre, global study assessing the efficacy and safety of rilvegostomig in combination with bevacizumab with or without tremelimumab compared to atezolizumab in combination with bevacizumab. Read more about this study

Who is it for?: Ages 18 years and older
Conditions the study is for: Hepatocellular Carcinoma
What is being tested?: Tremelimumab, Rilvegostomig and Bevacizumab
Type of treatment: Injection or infusion
Could I receive a placebo?: No, everyone receives an active treatment
How many people: 1,220 participants
Where: 226 sitesin 20 countries
Study dates: 6 May 2025to 15 Mar 2030
Phase: Phase 3
Are there results?: Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

Ages 18 years and older
All sexes
No healthy volunteers
Adult, Older adult

Who may be able to join

Locally advanced or metastatic and/or unresectable HCC
WHO/ECOG performance status of 0 or 1
BCLC stage B (that is not eligible for locoregional therapy) or stage C.
Child-Pugh Score class A
At least one measurable target lesion
Participants with active HBV infection must receive antiviral therapy for a minimum of 14 days prior to randomization to show evidence of HBV stabilization or signs of viral response.

Show all 11Show fewer

Participants with active HCV infection must be well controlled. Participants co-infected with HBV and HCV are not eligible.
Adequate organ and bone marrow function measured during the screening period.
Adequate organ and bone marrow function measured during the screening period
Must not have received prior systemic therapy for intermediate, advanced, or metastatic HCC.
Disease that is not amenable to curative surgical and/or locoregional therapies. For participants who received locoregional therapy for HCC, locoregional therapy must have been completed ≥ 28 days prior to the baseline scan for the current study.

Who cannot join

Medical condition
Any evidence of uncontrolled intercurrent diseases
Active or prior documented autoimmune or inflammatory disorders requiring chronic treatment with steroids or other immunosuppressive treatment
History of another primary malignancy
Persistent toxicities caused by previous anti-cancer therapy excluding alopecia, not yet improved to Grade ≤ 1 or baseline.
Clinically meaningful ascites, pleural effusion, or pericardial effusion requiring non-pharmacologic intervention to maintain symptomatic control within 6 months prior to the first scheduled dose.

Show all 17Show fewer

History of active primary immunodeficiency or active infection
History of hepatic encephalopathy
Current or recent (within 10 days of first dose of study treatment) use of aspirin (≥ 325 mg/day) or treatment with dipyridamole, ticlopidine, clopidogrel, and cilostazol
Current or recent (within 10 days prior to study treatment start) use of full-dose oral or parenteral anticoagulants or thrombolytic agents for therapeutic (as opposed to prophylactic) purposes is ineligible
History of significant bleeding disorders, vasculitis, or a significant bleeding episode from the GI tract within 6 months prior to study randomization.
Participants with untreated or incompletely treated varices with bleeding or high-risk (red wale signs or other high-risk factors) for bleeding.
HCC related
Known fibrolamellar HCC, sarcomatoid HCC, or mixed cholangiocarcinoma and HCC.
Central nervous system metastases or spinal cord compression (including asymptomatic and adequately treated disease)
Prior treatment with anti-CTLA-4 and/or anti-TIGIT.
Radiotherapy within 28 days and abdominal/ pelvic radiotherapy within 60 days prior to initiation of study treatment, except palliative radiotherapy to bone lesions within 7 days prior to initiation of study treatment

Trial locations and contacts

226 sites in 20 countries. Contact the study team or a site near you to ask about taking part.

AstraZeneca Clinical Study Information Center contact

1-877-240-9479

information.center@astrazeneca.com

Country

City, postcode or hospital

Sites recruiting now only

226 sites in 20 countries

United States37 sites, 33 recruiting

Research Site
Amarillo, Texas, 79124
Recruiting
Research Site
Arlington, Virginia, 22201
Recruiting
Research Site
Atlanta, Georgia, 30318
Recruiting
Research Site
Atlanta, Georgia, 30322
Withdrawn
Research Site
Austin, Texas, 78705
Recruiting
Research Site
Chicago, Illinois, 60637
Recruiting
Research Site
Cleveland, Ohio, 44195
Withdrawn
Research Site
Dallas, Texas, 75390
Withdrawn
Research Site
Denver, Colorado, 80210
Not yet recruiting
Research Site
Detroit, Michigan, 48202
Recruiting
Research Site
Grand Rapids, Michigan, 49503
Recruiting
Research Site
Honolulu, Hawaii, 96813
Withdrawn
Research Site
Houston, Texas, 77030
Recruiting
Research Site
Indianapolis, Indiana, 46202
Not yet recruiting
Research Site
Jacksonville, Florida, 32224
Recruiting
Research Site
Los Angeles, California, 90095
Recruiting
Research Site
Milwaukee, Wisconsin, 53226
Recruiting
Research Site
New Brunswick, New Jersey, 08901
Recruiting
Research Site
New Haven, Connecticut, 06520
Recruiting
Research Site
New York, New York, 10029
Recruiting
Research Site
New York, New York, 10032
Recruiting
Research Site
New York, New York, 10065
Not yet recruiting
Research Site
Newark, Delaware, 19713
Recruiting
Research Site
Oklahoma City, Oklahoma, 73104
Not yet recruiting
Research Site
Orlando, Florida, 32804
Not yet recruiting
Research Site
Palo Alto, California, 94304
Recruiting
Research Site
Philadelphia, Pennsylvania, 19107
Not yet recruiting
Research Site
Phoenix, Arizona, 85054
Recruiting
Research Site
Pittsburgh, Pennsylvania, 15232
Recruiting
Research Site
Rochester, Minnesota, 55905
Recruiting
Research Site
Salem, Virginia, 24153
Recruiting
Research Site
San Antonio, Texas, 78240
Recruiting
Research Site
Seattle, Washington, 98101
Recruiting
Research Site
Shreveport, Louisiana, 71103
Not yet recruiting
Research Site
St Louis, Missouri, 63108
Not yet recruiting
Research Site
Tucson, Arizona, 85719
Recruiting
Research Site
Tyler, Texas, 75702
Recruiting

Other trials in United States

China35 sites, 35 recruiting

Research Site
Beijing, 100034
Recruiting
Research Site
Beijing, 100142
Recruiting
Research Site
Beijing, CN-100730
Recruiting
Research Site
Changchun, 130021
Recruiting
Research Site
Changsha, 410013
Recruiting
Research Site
Chengdu, 610041
Recruiting
Research Site
Chifeng, 024000
Recruiting
Research Site
Chongqing, 400010
Recruiting
Research Site
Deyang, 618000
Recruiting
Research Site
Fuzhou, 350005
Recruiting
Research Site
Guangzhou, 510060
Recruiting
Research Site
Guangzhou, 510515
Recruiting
Research Site
Guiyang, 550002
Recruiting
Research Site
Harbin, 150081
Recruiting
Research Site
Hefei, 230022
Recruiting
Research Site
Hohhot, 010020
Recruiting
Research Site
Kunming, 650118
Not yet recruiting
Research Site
Linyi, 276000
Recruiting
Research Site
Lishui, 323000
Recruiting
Research Site
Luoyang, 471000
Recruiting
Research Site
Nanchang, 330008
Recruiting
Research Site
Nanchang, 330029
Recruiting
Research Site
Nanjing, 210029
Recruiting
Research Site
Nanning, 530021
Recruiting
Research Site
Nantong, 226361
Recruiting
Research Site
Neijiang, 641100
Recruiting
Research Site
Shandong
Recruiting
Research Site
Shanghai, 201114
Recruiting
Research Site
Shenyang, 110004
Recruiting
Research Site
Shenyang, 110042
Recruiting
Research Site
Weifang, 261000
Recruiting
Research Site
Wenzhou, 325000
Recruiting
Research Site
Wuhan, 430079
Recruiting
Research Site
Xi'an, 710100
Recruiting
Research Site
Zhengzhou, 450008
Recruiting

Other trials in China

Japan30 sites, 30 recruiting

Research Site
Bunkyō City, 113-8655
Recruiting
Research Site
Chiba, 260-8677
Recruiting
Research Site
Fukuoka, 811-1395
Recruiting
Research Site
Hiroshima, 734-8530
Recruiting
Research Site
Hiroshima, 734-8551
Recruiting
Research Site
Iizuka-shi, 820-8505
Recruiting
Research Site
Kashiwa, 227-8577
Recruiting
Research Site
Kita-gun, 761-0793
Recruiting
Research Site
Kobe, 650-0017
Recruiting
Research Site
Kōtoku, 135-8550
Recruiting
Research Site
Kumamoto, 860-8556
Recruiting
Research Site
Kurume-shi, 830-0011
Recruiting
Research Site
Kyoto, 602-8566
Recruiting
Research Site
Matsuyama, 790-0024
Recruiting
Research Site
Mitaka-shi, 181-8611
Recruiting
Research Site
Morioka, 028-3695
Recruiting
Research Site
Musashino-shi, 180-8610
Recruiting
Research Site
Nagoya, 464-8681
Recruiting
Research Site
Okayama, 700-8558
Recruiting
Research Site
Osaka, 541-8567
Recruiting
Research Site
Osakasayama-shi, 589-8511
Recruiting
Research Site
Saga, 849-8501
Recruiting
Research Site
Sapporo, 006-8555
Recruiting
Research Site
Sendai, 981-0914
Recruiting
Research Site
Suita-shi, 565-0871
Recruiting
Research Site
Tokyo, 104-0045
Recruiting
Research Site
Toyoake-shi, 470-1192
Recruiting
Research Site
Tsu, 514-8507
Recruiting
Research Site
Yokohama, 232-0024
Recruiting
Research Site
Yokohama, 241-8515
Recruiting

Other trials in Japan

Germany22 sites, 20 recruiting

Research Site
Aachen, 52074
Recruiting
Research Site
Berlin, 13353
Recruiting
Research Site
Bonn, 53127
Recruiting
Research Site
Chemnitz, 09116
Not yet recruiting
Research Site
Cologne, 50937
Not yet recruiting
Research Site
Dortmund, 44137
Recruiting
Research Site
Dresden, 01307
Recruiting
Research Site
Erlangen, 91054
Not yet recruiting
Research Site
Essen, 45122
Recruiting
Research Site
Frankfurt, 60488
Recruiting
Research Site
Frankfurt, 60590
Recruiting
Research Site
Göttingen, 37075
Suspended
Research Site
Hamburg, 20246
Not yet recruiting
Research Site
Hanover, 30623
Recruiting
Research Site
Leipzig, 4103
Recruiting
Research Site
Lübeck, 23538
Recruiting
Research Site
Magdeburg, 39120
Recruiting
Research Site
Moers, 47441
Recruiting
Research Site
München, 81377
Recruiting
Research Site
Munich, 80336
Not yet recruiting
Research Site
Regensburg, 93053
Withdrawn
Research Site
Ulm, 89081
Recruiting

Other trials in Germany

Canada9 sites, 8 recruiting

Research Site
Barrie, Ontario, L4M 6M2
Recruiting
Research Site
Brampton, Ontario, L6R 3J7
Recruiting
Research Site
Cambridge, Ontario, N1R 3G2
Not yet recruiting
Research Site
Edmonton, Alberta, T6G 1Z2
Recruiting
Research Site
Halifax, Nova Scotia, B3H 1V7
Not yet recruiting
Research Site
Montreal, Quebec, H2X 0A9
Recruiting
Research Site
Ottawa, Ontario, K1H 8L6
Withdrawn
Research Site
Québec, Quebec, G1J 1Z4
Recruiting
Research Site
Toronto, Ontario, M5G 1X6
Recruiting

Other trials in Canada

France9 sites, 9 recruiting

Research Site
Clichy, 92118
Recruiting
Research Site
Lille, 59000
Recruiting
Research Site
Lyon, 69317
Recruiting
Research Site
Montpellier, 34090
Recruiting
Research Site
Nantes, 44093
Recruiting
Research Site
Nice, 06200
Recruiting
Research Site
Pessac, 33604
Recruiting
Research Site
Rennes, 35000
Recruiting
Research Site
Toulouse, 31059
Recruiting

Other trials in France

India9 sites, 8 recruiting

Research Site
Ahmedabad, 380058
Recruiting
Research Site
Bangalore, 560027
Withdrawn
Research Site
Binnāguri, 734015
Not yet recruiting
Research Site
Dehradun, 248016
Not yet recruiting
Research Site
Delhi, 110029
Not yet recruiting
Research Site
Hyderabad, 500032
Not yet recruiting
Research Site
Mumbai, 400012
Recruiting
Research Site
Nashik, 422011
Recruiting
Research Site
Vadodara, 391760
Recruiting

Other trials in India

Italy8 sites, 8 recruiting

Research Site
Bologna, 40138
Recruiting
Research Site
Milan, 20132
Recruiting
Research Site
Milan, 20162
Recruiting
Research Site
Palermo, 90127
Recruiting
Research Site
Perugia, 06132
Recruiting
Research Site
Pisa, 56126
Recruiting
Research Site
Roma, 00168
Recruiting
Research Site
Rozzano, 20089
Recruiting

Other trials in Italy

South Korea8 sites, 8 recruiting

Research Site
Busan, 48108
Recruiting
Research Site
Goyang-si, 410-769
Not yet recruiting
Research Site
Gyeonggi-do, 13620
Not yet recruiting
Research Site
Seongnam-si, 463-712
Recruiting
Research Site
Seoul, 03080
Not yet recruiting
Research Site
Seoul, 03722
Recruiting
Research Site
Seoul, 06351
Recruiting
Research Site
Seoul, 5505
Recruiting

Other trials in South Korea

Taiwan8 sites, 8 recruiting

Research Site
Changhua, 500
Recruiting
Research Site
Kaohsiung City, 83301
Recruiting
Research Site
Taichung, 40447
Recruiting
Research Site
Tainan, 70403
Recruiting
Research Site
Tainan County, 71044
Recruiting
Research Site
Taipei, 10002
Recruiting
Research Site
Taipei, 112
Recruiting
Research Site
Taoyuan, 333
Recruiting

Other trials in Taiwan

Thailand7 sites, 5 recruiting

Research Site
Bangkok, 10210
Withdrawn
Research Site
Bangkok, 10700
Recruiting
Research Site
Chiang Mai, 50200
Recruiting
Research Site
Dusit, 10300
Recruiting
Research Site
Hat Yai, 90110
Recruiting
Research Site
Muang, 40002
Recruiting
Research Site
Ubonratchathani, 34000
Withdrawn

Other trials in Thailand

Brazil6 sites, 6 recruiting

Research Site
Barretos, 14784-400
Recruiting
Research Site
Porto Alegre, 91350-200
Recruiting
Research Site
Santa Maria, 97015-450
Recruiting
Research Site
São Paulo, 04014-002
Recruiting
Research Site
São Paulo, 05652-9000
Recruiting
Research Site
Vitória, 29043-272
Recruiting

Other trials in Brazil

Poland6 sites, 6 recruiting

Research Site
Bydgoszcz, 85-796
Not yet recruiting
Research Site
Gdansk, 80-214
Recruiting
Research Site
Koszalin, 75-581
Recruiting
Research Site
Lublin, 20-090
Recruiting
Research Site
Olsztyn, 10-228
Recruiting
Research Site
Warsaw, 02-034
Recruiting

Other trials in Poland

Spain6 sites, 6 recruiting

Research Site
Barcelona, 08035
Recruiting
Research Site
Barcelona, 08036
Recruiting
Research Site
Madrid, 28007
Recruiting
Research Site
Madrid, 28027
Recruiting
Research Site
Madrid, 28040
Recruiting
Research Site
Santander, 39008
Recruiting

Other trials in Spain

Turkey (Türkiye)6 sites, 5 recruiting

Research Site
Altındağ, 06230
Recruiting
Research Site
Ankara, 06530
Recruiting
Research Site
Erzurum, 25240
Recruiting
Research Site
Istanbul, 34180
Withdrawn
Research Site
Istanbul, 34899
Recruiting
Research Site
Izmir, 35100
Recruiting

Other trials in Turkey (Türkiye)

United Kingdom6 sites, 6 recruiting

Research Site
Cambridge, CB2 0QQ
Recruiting
Research Site
Leeds, LS9 7TF
Recruiting
Research Site
London, NW3 2QG
Recruiting
Research Site
London, SE5 9RS
Recruiting
Research Site
London, W12 0HS
Recruiting
Research Site
Manchester, M20 4BX
Recruiting

Other trials in United Kingdom

Australia5 sites, 5 recruiting

Research Site
Camperdown, 2050
Recruiting
Research Site
Clayton, 3168
Recruiting
Research Site
Heidelberg, 3084
Recruiting
Research Site
Randwick, 2031
Recruiting
Research Site
South Brisbane, 4101
Recruiting

Other trials in Australia

Netherlands5 sites, 4 recruiting

Research Site
Amsterdam, 1081HV
Recruiting
Research Site
Groningen, 9700 RB
Recruiting
Research Site
Maastricht, 6229 HX
Recruiting
Research Site
Rotterdam, 3015 GD
Withdrawn
Research Site
Utrecht, 3584 CX
Recruiting

Other trials in Netherlands

Vietnam3 sites, 2 recruiting

Research Site
Hanoi, 100000
Recruiting
Research Site
Hanoi, 100000
Withdrawn
Research Site
Ho Chi Minh City, 700000
Recruiting

Other trials in Vietnam

Hong Kong1 site, 1 recruiting

Research Site
Hong Kong, 999077
Recruiting

Other trials in Hong Kong

About this study

Official title: A Phase III, Randomised, Open-label, Sponsor-blinded, Multicentre Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma

Read the detailed description

The purpose of this study is to assess the efficacy and tolerability of rilvegostomig in combination with bevacizumab with or without tremelimumab as first-line treatment in participants with advanced HCC. The study comprises 2 parts - a safety lead-in and a randomised period. Prior to the start of the randomised period of the study, a single-arm safety lead-in period will be applied to evaluate the safety and tolerability of rilvegostomig in combination with bevacizumab and tremelimumab.

Conditions: Hepatocellular Carcinoma
Being tested: Tremelimumab, Rilvegostomig, Bevacizumab, Atezolizumab
Medical subject headings: Carcinoma, Hepatocellular

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

TremelimumabDrug
IV therapy
RilvegostomigDrug
IV therapy
BevacizumabDrug
IV therapy
AtezolizumabDrug
IV therapy

Study groups in NCT06921785
Study group	Role	What they receive
Arm A	Experimental	Tremelimumab , rilvegostomig and bevacizumab Receives: Drug: Tremelimumab; Drug: Rilvegostomig; Drug: Bevacizumab
Arm B	Experimental	Rilvegostomig, and bevacizumab Receives: Drug: Rilvegostomig; Drug: Bevacizumab
Arm C	Active comparator	Atezolizumab, and bevacizumab Receives: Drug: Bevacizumab; Drug: Atezolizumab

What is being measured

The primary outcome is the main question the study is designed to answer.

To demonstrate the efficacy of Arm A relative to Arm C by assessment of OS in participants with advanced HCC
OS is defined as the time from randomisation until the date of death due to any cause.
Measured: Up to approximately 6 years

Secondary outcomes (16)

To demonstrate the efficacy of Arm B relative to Arm C by assessment of OS in participants with advanced HCC
OS is defined as the time from randomisation until the date of death due to any cause.
Measured: Up to approximately 6 years
To further demonstrate the efficacy of Arm A relative to Arm C and Arm B relative to Arm C in participants with advanced HCC
PFS according to RECIST 1.1
Measured: Up to approximately 6 years
To further demonstrate the efficacy of Arm A relative to Arm C and Arm B relative to Arm C in participants with advanced HCC
ORR according to RECIST 1.1
Measured: Up to approximately 6 years
To further demonstrate the efficacy of Arm A relative to Arm C and Arm B relative to Arm C in participants with advanced HCC
DoR according to RECIST 1.1
Measured: Up to approximately 6 years
To demonstrate the efficacy of Arm A relative to Arm B in participants with advanced HCC
OS
Measured: Up to approximately 6 years
To demonstrate the efficacy of Arm A relative to Arm B in participants with advanced HCC
PFS
Measured: Up to approximately 6 years
To demonstrate the efficacy of Arm A relative to Arm B in participants with advanced HCC
ORR
Measured: Up to approximately 6 years
To demonstrate the efficacy of Arm A relative to Arm B in participants with advanced HCC
DoR
Measured: Up to approximately 6 years
To demonstrate the efficacy of Arm A relative to Arm C in the population defined by PD-L1 expression subgroups
Association of PD-L1 expression level with:
- OS
Measured: Up to approximately 6 years
To demonstrate the efficacy of Arm A relative to Arm C in the population defined by PD-L1 expression subgroups
Association of PD-L1 expression level with:
- PFS per RECIST 1.1
Measured: Up to approximately 6 years
To demonstrate the efficacy of Arm A relative to Arm C in the population defined by PD-L1 expression subgroups
Association of PD-L1 expression level with:
- ORR per RECIST 1.1
Measured: Up to approximately 6 years
To demonstrate the efficacy of Arm B relative to Arm C in the population defined by PD-L1 expression subgroups
Association of PD-L1 expression level with:
OS
Measured: Up to approximately 6 years
To demonstrate the efficacy of Arm B relative to Arm C in the population defined by PD-L1 expression subgroups
Association of PD-L1 expression level with:
PFS per RECIST 1.1
Measured: Up to approximately 6 years
To demonstrate the efficacy of Arm B relative to Arm C in the population defined by PD-L1 expression subgroups
Association of PD-L1 expression level with:
ORR per RECIST 1.1
Measured: Up to approximately 6 years
To investigate the immunogenicity of Arm A and Arm B
Presence of ADAs for tremelimumab and rilvegostomig
Measured: Up to approximately 6 years
Occurrence of adverse events (AEs) and serious adverse events (SAEs)
Occurrence of AEs and SAEs will be graded according to the revised NCI CTCAE v5.0.
Measured: Up to approximately 6 years

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

6 May 202515 Mar 2030

First posted10 Apr 2025
Study start6 May 2025
Primary completion15 Mar 2030 (estimated)
Study completion15 Mar 2030 (estimated)

Resources

Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
Other trials for Hepatocellular CarcinomaStudies of the same condition, open and under way.
More trials run by AstraZenecaThe sponsor's other registered studies.
What the trial phases meanHow a treatment moves from first tests in people to approval.

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design

Study type: Interventional
Phase: Phase 3
Primary purpose: Treatment
Allocation: Randomised
Intervention model: Parallel groups
Masking: Single blind
Who is masked: Outcomes assessor
Enrolment: 1,220 participants (estimated)

IDs, dates and publications

ClinicalTrials.gov ID: NCT06921785
Sponsor's protocol ID: D7029C00001
Acronym: ARTEMIDE-HCC01
Status last verified: Oct 2026
First submitted: 26 Mar 2025
Last updated: 13 Oct 2026
Results posted: No
Data monitoring committee: Yes
FDA-regulated drug: Yes
FDA-regulated device: No
Individual data sharing: Yes: Qualified researchers can request access to anonymized individualpatient-level data from AstraZeneca group of companies sponsoredclinical trials via the request portal Vivli.org. All requests will be evaluatedas per the AZ disclosure commitment:https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.Yes, indicates that AZ are accepting requests for IPD, but this does notmean all requests will be shared.

Interested in taking part?

AstraZeneca Clinical Study Information Center

1-877-240-9479

information.center@astrazeneca.com

Talk to your doctor first and take this page with you. Only the study team can confirm whether you can join.

Questions to ask the study team

What is the study trying to find out?
What would I need to do, and how often would I visit?
Could I receive a placebo instead of the treatment?
What are the possible risks and benefits for me?
Will it cost me anything? Are travel or time paid for?
Can I keep seeing my own doctor during the study?
What happens when the study ends?

See sites and contacts

RecruitingObservational study
Real-world Evaluation of the HistoSonics Edison System for Treatment of Liver Tumors Across Multidisciplinary Users (BOOMBOX: Master Study)
Liver Neoplasms, Primary Liver Cancer
Recruiting
The Vanguard Study: Testing a New Way to Screen for Cancer
Bladder Carcinoma, Breast Carcinoma
Active, not recruitingPhase 1
Prospective Exploratory Study of FAPi PET/CT With Histopathology Validation in Patients With Various Cancers
Bladder Carcinoma, Cervical Carcinoma
RecruitingObservational study
A Study to Evaluate Patient-Reported Satisfaction, Effectiveness, and Safety of Atezolizumab in Participants Treated in Routine Clinical Practice
Lung Cancer, Hepatocellular Carcinoma
RecruitingPhase 2
At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer
Advanced Anal Carcinoma, Advanced Biliary Tract Carcinoma

All Hepatocellular Carcinoma trials

Study at a glance

From the registry record, last updated by the sponsor on 13 Oct 2026. Recruitment status is as the sponsor reported it: confirm with the study team.

Official title: A Phase III, Randomised, Open-label, Sponsor-blinded, Multicentre Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma
ClinicalTrials.gov ID: NCT06921785
Acronym / sponsor ID: ARTEMIDE-HCC01 / D7029C00001
Conditions: Hepatocellular Carcinoma
Phase: Phase 3
Study type: Interventional
Recruitment status: Recruiting
Enrolment: 1,220 participants (estimated)
Lead sponsor: AstraZenecaIndustry (pharma, biotech, devices)
Study start: 6 May 2025 (actual)
Primary completion: 15 Mar 2030 (estimated)
Study completion: 15 Mar 2030 (estimated)
First posted: 10 Apr 2025 (actual)
Results: Not posted in the source record

Clinical summary

The research question as the sponsor registered it. This describes what the study plans to test, not what it found.

Detailed description

Study design

Primary purpose: Treatment
Allocation: Randomised
Intervention model: Parallel groups
Masking: Single blind (outcomes assessor)
Number of arms: 3

Arm	Type	Receives
Arm A	Experimental	Drug: Tremelimumab, Drug: Rilvegostomig, Drug: BevacizumabTremelimumab , rilvegostomig and bevacizumab
Arm B	Experimental	Drug: Rilvegostomig, Drug: BevacizumabRilvegostomig, and bevacizumab
Arm C	Active comparator	Drug: Bevacizumab, Drug: AtezolizumabAtezolizumab, and bevacizumab

Who may qualify

Ages: 18 years and older
Sex: All
Healthy volunteers: Not accepted
Age groups: Adult, Older adult

Key inclusion criteria (11 listed)

Locally advanced or metastatic and/or unresectable HCC
WHO/ECOG performance status of 0 or 1
BCLC stage B (that is not eligible for locoregional therapy) or stage C.
Child-Pugh Score class A
At least one measurable target lesion

Key exclusion criteria (17 listed)

Medical condition
Any evidence of uncontrolled intercurrent diseases
Active or prior documented autoimmune or inflammatory disorders requiring chronic treatment with steroids or other immunosuppressive treatment
History of another primary malignancy
Persistent toxicities caused by previous anti-cancer therapy excluding alopecia, not yet improved to Grade ≤ 1 or baseline.

Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.

Interventions

Intervention	Type	Arms
TremelimumabIV therapy	Drug	Arm A
RilvegostomigIV therapy	Drug	Arm A, Arm B
BevacizumabIV therapy	Drug	Arm A, Arm B, Arm C
AtezolizumabIV therapy	Drug	Arm C

Primary outcome

To demonstrate the efficacy of Arm A relative to Arm C by assessment of OS in participants with advanced HCC
Time frame: Up to approximately 6 years
OS is defined as the time from randomisation until the date of death due to any cause.

16 secondary outcomes

To demonstrate the efficacy of Arm B relative to Arm C by assessment of OS in participants with advanced HCC
Time frame: Up to approximately 6 years
To further demonstrate the efficacy of Arm A relative to Arm C and Arm B relative to Arm C in participants with advanced HCC
Time frame: Up to approximately 6 years
To further demonstrate the efficacy of Arm A relative to Arm C and Arm B relative to Arm C in participants with advanced HCC
Time frame: Up to approximately 6 years
To further demonstrate the efficacy of Arm A relative to Arm C and Arm B relative to Arm C in participants with advanced HCC
Time frame: Up to approximately 6 years
To demonstrate the efficacy of Arm A relative to Arm B in participants with advanced HCC
Time frame: Up to approximately 6 years
To demonstrate the efficacy of Arm A relative to Arm B in participants with advanced HCC
Time frame: Up to approximately 6 years
To demonstrate the efficacy of Arm A relative to Arm B in participants with advanced HCC
Time frame: Up to approximately 6 years
To demonstrate the efficacy of Arm A relative to Arm B in participants with advanced HCC
Time frame: Up to approximately 6 years
To demonstrate the efficacy of Arm A relative to Arm C in the population defined by PD-L1 expression subgroups
Time frame: Up to approximately 6 years
To demonstrate the efficacy of Arm A relative to Arm C in the population defined by PD-L1 expression subgroups
Time frame: Up to approximately 6 years
To demonstrate the efficacy of Arm A relative to Arm C in the population defined by PD-L1 expression subgroups
Time frame: Up to approximately 6 years
To demonstrate the efficacy of Arm B relative to Arm C in the population defined by PD-L1 expression subgroups
Time frame: Up to approximately 6 years
To demonstrate the efficacy of Arm B relative to Arm C in the population defined by PD-L1 expression subgroups
Time frame: Up to approximately 6 years
To demonstrate the efficacy of Arm B relative to Arm C in the population defined by PD-L1 expression subgroups
Time frame: Up to approximately 6 years
To investigate the immunogenicity of Arm A and Arm B
Time frame: Up to approximately 6 years
Occurrence of adverse events (AEs) and serious adverse events (SAEs)
Time frame: Up to approximately 6 years

Results and safety

This study is still under way. Results are not available in the source record yet.

Research links

Official record on ClinicalTrials.govLast updated by the sponsor 13 Oct 2026.
Individual participant dataSharing planned: Yes. Qualified researchers can request access to anonymized individualpatient-level data from AstraZeneca group of companies sponsoredclinical trials via the request portal Vivli.org. All requests will be evaluatedas per the AZ disclosure commitment:https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.Yes, indicates that AZ are accepting requests for IPD, but this does notmean all requests will be shared.

Related trials for Hepatocellular Carcinoma

RecruitingObservational study
Real-world Evaluation of the HistoSonics Edison System for Treatment of Liver Tumors Across Multidisciplinary Users (BOOMBOX: Master Study)
Liver Neoplasms, Primary Liver Cancer
Recruiting
The Vanguard Study: Testing a New Way to Screen for Cancer
Bladder Carcinoma, Breast Carcinoma
Active, not recruitingPhase 1
Prospective Exploratory Study of FAPi PET/CT With Histopathology Validation in Patients With Various Cancers
Bladder Carcinoma, Cervical Carcinoma
RecruitingObservational study
A Study to Evaluate Patient-Reported Satisfaction, Effectiveness, and Safety of Atezolizumab in Participants Treated in Routine Clinical Practice
Lung Cancer, Hepatocellular Carcinoma
RecruitingPhase 2
At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer
Advanced Anal Carcinoma, Advanced Biliary Tract Carcinoma

Referral and contact

AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.

AstraZeneca Clinical Study Information Center contact

1-877-240-9479

information.center@astrazeneca.com

226 sites in 20 countries: see every site and its status.

Questions about this trial

What is this clinical trial studying?

A Phase 3 study testing Tremelimumab, Rilvegostomig and Bevacizumab in people with Hepatocellular Carcinoma, run by AstraZeneca at 226 sites in 20 countries.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 11 inclusion and 17 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: looking for participants now, as of the sponsor's last update on 13 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 226 sites in United States, China, Japan, Germany, Canada and 15 more countries. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact AstraZeneca Clinical Study Information Center (1-877-240-9479, information.center@astrazeneca.com), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

To demonstrate the efficacy of Arm A relative to Arm C by assessment of OS in participants with advanced HCC (time frame: Up to approximately 6 years). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT06921785.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 13 Oct 2026.